<DOC>
	<DOCNO>NCT00117702</DOCNO>
	<brief_summary>The purpose pilot study provide preliminary data efficacy safety combination tacrolimus everolimus prophylaxis graft-versus-host-disease ( GvHD ) patient allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Prevention Graft-Versus-Host-Disease Patients After Stem Cell Transplantation With Tacrolimus Everolimus</brief_title>
	<detailed_description>The allogeneic stem cell transplantation successful therapeutic approach treatment number hematologic disease . Nevertheless , associate substantial risk complication . A major life-threatening complication occur post transplantation period graft versus host disease , especially severe form ( Grade III Grade IV ) . For reason , combine immunosuppressive therapy standard patient stem cell transplantation . In regard , combination cyclosporin A methotrexate prevention GvHD particularly successful . However , incidence rate GvHD consequent mortality still fairly high . Besides , therapy accompany serious side effect . Therefore , need efficient , less toxic , combined immunosuppressive therapy . The purpose pilot study test new combination immunosuppressive ( tacrolimus everolimus ) prevention GvHD allogeneic stem cell transplantation . Tacrolimus macrolide immunosuppressant act calcineurin inhibitor , thereby prevent activation proliferation T-lymphocytes . Everolimus semisynthetic macrocyclic lactone inhibit activity key protein involve regulation cell cycle , call m-TOR protein . Both medicament act complementary potently inhibit proliferation immune cell . Previous study show combination tacrolimus everolimus decrease significantly rejection rate solid organ transplantation combination generally well tolerate . This study design prospective , single-center , non-randomized , open-label non-controlled pilot study . Study relate visit schedule take place regular time interval patient follow one year stem cell transplantation . The study design conduct accordance ICH-GCP guideline respective national international law .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female patient 18 70 year age Planned allogeneic stem cell transplantation either relate unrelated donor Written inform consent Previous stem cell transplantation Use antibody Campath ( anti CD52 ) ATG conditioning In vitro Tcell deplete graft Known hypersensitivity everolimus constituent study medication Symptomatic infectious disease Hepatic disease ( ASAT &gt; 2 x ULN ) Renal insufficiency ( creatinine &gt; 2 x ULN ) HIV infection Life expectancy &lt; 3 month Severe lung disease ( FEV1 &lt; 50 % normal value ) Severe psychiatric disorder Subjects unlikely comply requirement protocol Known current alcohol , medication drug abuse Pregnancy lactation Women childbearing potential without reliable contraception unless meet follow criterion : postmenopausal ( 12 month natural amenorrhea ) ; postoperation status ( 6 week surgical bilateral oophorectomy without hysterectomy ) ; use highly effective birth control method ( define one result low failure rate i.e . le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomize partner ) Men use one follow method prevention conception : sexual abstinence ; condom ; vasectomy Participation subject another clinical trial within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>GvHD</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Stem cell transplantation</keyword>
</DOC>